Vareum

Vareum is a clinical-stage biotechnology company dedicated to developing a new class of small molecule medicines targeting chronic inflammatory and fibrotic diseases. The company's primary focus is on the inhibition of Vascular Adhesion Protein-1 (VAP-1), an enzyme that plays a critical role in leukocyte recruitment and oxidative stress within inflamed tissues. Their lead candidate, VRM-001, is currently being evaluated in Phase 2 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. By targeting the root causes of tissue remodeling, Vareum aims to provide transformative therapies for patients with high unmet needs in liver, lung, and kidney diseases.